CDH17 and hepatocellular carcinoma: In vivo data shows that KD of CDH17 in xenograft models reduced tumour growth by 80–95% [6,20], while antibody-based inhibition with Lic5 led to over 50% tumour reduction and synergized with cisplatin to achieve almost complete suppression in HCC models [30].